**Author details**

Guy Rostoker1\*, Mireille Griuncelli1 , Christelle Loridon1 and Yves Cohen2

\*Address all correspondence to: rostotom@orange.fr

1 Division of Nephrology and Dialysis, HP Claude Galien, Ramsay Générale de Santé, Quincy sous Sénart, France

2 Division of Radiology, HP Claude Galien, Ramsay Générale de Santé, Quincy sous Sénart, France

## **References**

targets aimed at "repleting exaggerately" iron stores [6,7]. A new pharmacometric and economic approach to iron therapy has recently been advocated [6,7,26,58]. Moreover, the KDIGO Controversies Conference on Iron Management in Chronic Kidney Disease, which took place in San Francisco on March 27-30, 2014 and was attended by nephrologists, hema‐ tologists, hepatologists and specialists in iron metabolism, recognized the entity of iron overload in hemodialysis patients and called for an agenda of research on this topic, especially by means of MRI [63]. Analysis of liver iron content in dialysis patients by means of quanti‐ tative MRI, a new research tool that overcomes a major hypothetical limitation in hemodialysis patients, namely bone marrow iron depletion despite severe hepatosplenic siderosis, and allows safe non aggressive iterative "radiological liver biopsy" might, in combination with data-mining statistical methods and classical statistical methods such as AUC determination and logistic regression, allow nephrologists to determine both a non toxic dose of infused iron and relevant target values for biological markers of iron metabolism, thereby improving the safety of parenteral iron products in dialysis patients [6,7,26,58, 63]. Finally, specific MRI protocols need to be established in radiology and nephrology divisions for each pharmaceut‐

Parts of the chapter are reproduced from the authors' previous publication "Maximal Stand‐ ard Dose of Parenteral Iron for Hemodialysis Patients: An MRI-Based Decision Tree Learn‐ ing Analysis" Guy Rostoker, Mireille Griuncelli, Christelle Loridon, Théophile Magna,

PLoS One. 2014 Dec 15; 9(12):e115096. doi: 10.1371/journal.pone.0115096. eCollection 2014.

Parts of the chapter are reproduced from the authors' previous publication "Hemodialysisassociated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study." Ros‐ toker G1, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Am J Med. 2012 Oct; 125(10):991-999.e1. doi:

, Christelle Loridon1

1 Division of Nephrology and Dialysis, HP Claude Galien, Ramsay Générale de Santé, Quincy

2 Division of Radiology, HP Claude Galien, Ramsay Générale de Santé, Quincy sous Sénart,

and Yves Cohen2

ical iron product, in order to avoid spurious results [47].

Philippe Janklewicz, Gilles Drahi, Hervé Dahan, Yves Cohen.

**Permissions**

70 Updates in Hemodialysis

10.1016/j.amjmed.2012.01.015.

Guy Rostoker1\*, Mireille Griuncelli1

\*Address all correspondence to: rostotom@orange.fr

**Author details**

sous Sénart, France

France


[14] Scientific advisory committee on nutrition. Iron and health. 2010, London, TSO.

ulator of iron metabolism. Nature Genet 2014; 46(7): 678-684

chronic renal failure. Am J Kidney Dis 1982; 1(4): 232-236

logica 2013; 98 (6): 845-853

disease. Submitted for publication

Nephrol 1989; 9 (1 Suppl 2): 21-24

104. First published online: May 12, 2014.

US hemodialysis patients. Am J Med 2012; 125(9): 906-914

Nephrol Dial Transplant 2013; 28(10): 2570-2579

22(1): 112-123

72 Updates in Hemodialysis

[15] Kautz L, Jung G, Valore EV et al. Identification of erythroferrone as an erythroid reg‐

[16] De Falco L, Sanchez M, Silvestri L et al. Iron refractory deficiency anemia. Haemato‐

[17] Sargent JA and Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004;

[18] Otti T, Khajehdehi P, Fawzy A et al. Comparison of blood loss with different highflux and high-efficiency hemodialysis membranes. Am J Nephrol 2001; 21(1): 16-19

[19] Kalocheretis P, Vlamis I, Belesi C et al. Residual blood loss in single use dialyzers: effect of different membranes and flux. Int J Artif Organs 2006; 29(3): 286-292

[20] Rottembourg J and Rostoker G. Use of intravenous iron products in chronic kidney

[21] Rosenblatt SG, Drake S, Fadem S et al. Gastrointestinal blood loss in patients with

[22] Flint S, Taylor E, Beavis J et al. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin. Nephron Clin Pract 2009; 113(1): c38-c45

[23] Goicoechea M, Caramelo C, Ochando A, et al. Antiplatelet therapy alters iron re‐

[24] Anastassiades EG, Howarth D, Howarth J et al. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial transplant 1993; 8(9): 846-853

[25] Van Wyck DB. Iron deficiency in patients with dialysis–associated anemia during er‐ ythropoietin replacement therapy: strategies for assessment and management. Semin

[26] Gaweda AE, Ginzburg YZ, Chait Y et al. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 2014; doi 10.1093/ndt/gfu

[27] Freburger JK, Ng LJ, Bradbury B et al. Changing patterns of anemia management in

[28] Pisoni RL, Fuller DS, Bieber BA et al. The DOPPS practice monitor for US dialysis care: trends through August 2011. Am J Kidney Diseases 2012; 60(1): 160-165

[29] Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use interna‐ tionally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

quirements in hemodialysis patients. Am J Kidney Dis 2000; 36(1): 80-87


[59] Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemo‐ dialysis-associated inflammation. Hemodial Int 2005; 9(1): 37-46

[45] St Pierre TG, Clark PR, Chua-Anusom W et al. Noninvasive measurement and imag‐ ing of liver iron concentrations using proton magnetic resonance. Blood 2005; 105(2):

[46] Wood JC, Enriquez C, Ghugre N et al. MRI R2 and R2\*mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell dis‐

[47] Rostoker G and Cohen Y. Magnetic resonance imaging repercussions of intravenous iron products used for iron-deficiency anemia and dialysis-associated anemia. J

[48] Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(1): 77-83 [49] Ghoti H, Rachmilewitz EA, Simon-Lopez R et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur

[50] Canavese C, Bergamo D, Ciccone G et al. Validation of serum ferritin values by mag‐ netic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004;

[51] Fishbane S, Miyawaki N, Masani N. Hepatic iron in hemodialysis patients. Kidney

[52] Kuo KL, Hung SC, Lin YP et al. Intravenous ferric chloride hexahydrate supplemen‐ tation induced endothelial dysfunction and increased cardiovascular risk among he‐

[53] Kuragano T, Matsumura O, Matsuda A et al. Association between hemoglobin varia‐ bility, serum ferritin levels, and adverse events/mortality in maintenance hemodialy‐

[54] Bailie GR, Larkina M, Goodkin DA et al. Data from the Dialysis Outcomes and Prac‐ tice Patterns Study validate an association between high intravenous iron doses and

[55] Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus mainte‐ nance iron supplementation in hemodialysis patients. JASN 2013; 24(7): 1151-1158

[56] Valenti L, Messa P, Pelusi S et al. Hepcidin levels in chronic hemodialysis patients: a

[57] Van der Weerd NC, Grooteman MP, Bots ML et al. Hepcidin-25 is related to cardio‐ vascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;

[58] Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients.

sis patients. Kidney International, 23 april 2014; doi: 10.1038/ki.2014.114

mortality. Kidney Int 30 july 2014 /doi: 10.1038 /ki.2014.275

critical evaluation. Clin Chem and Lab Med 2014; 52(5): 613-619

Nephrol Dial Transplant 2014; 29(2): 255-259.

ease patients. Blood 2005; 106(4): 1460-1465

Comp Assist Tomogr 2014, Sept 16

J Haematol 2012; 89(1): 87-93

Int 2004; 66(4): 1714-1715

modialysis patients. PloS One 2012; 7(12): e50295

65(3): 1091-1098

28(12): 3062-3071

855-861

74 Updates in Hemodialysis


**Chapter 5**
